Significance of chemoprevention for prostate cancer development: Experimental in vivo approaches to chemoprevention

Pathology International

Volumn 58, Issue 1, 2008, Pages 1-16

  Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Animal model; Chemoprevention; Latent cancer; Prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ANGIOTENSIN RECEPTOR; BETA CAROTENE; CATECHIN; CURCUMIN; DUTASTERIDE; FINASTERIDE; GAMMA TOCOPHEROL; GREEN TEA EXTRACT; ISOFLAVONE; LYCOPENE; PHENOL DERIVATIVE; RESVERATROL; SELENIUM; TESTOSTERONE;

CANCER PATIENT; CANCER RISK; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; IN VIVO STUDY; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; REVIEW;

ANIMALS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RATS;

EID: 36649027457     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2007.02182.x     Document Type: Review

References (115)

1. Society AC. Cancer facts and figures 2007. Available at http://www.cancer.org/. 2007 17 19.
2. Marugame T, Mizuno S. Comparison of prostate cancer mortality in five countries. France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol 2005 35 : 690 91.
3. Takahashi S, Shirai T, Hasegawa R, Imaida K, Ito N. Latent prostatic carcinomas found at autopsy in men over 90 years old. Jpn J Clin Oncol 1992 22 : 117 21.
4. Yatani R, Kusano I, Shiraishi T, Hayashi T, Stemmermann GN. Latent prostatic carcinoma: Pathological and epidemiological aspects. Jpn J Clin Oncol 1989 19 : 319 26.
5. Park SK, Sakoda LC, Kang D et al. Rising prostate cancer rates in South Korea. Prostate 2006 66 : 1285 91.
6. Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J. Changing trends of prostate cancer in Asia. Aging Male 2004 7 : 120 32.
7. Pu YS. Prostate cancer in Taiwan: Epidemiology and risk factors. Int J Androl 2000 23 : 34 6.
8. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999 161 : 152 5.
9. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991 63 : 963 6.
10. Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982 29 : 611 16.
11. Shiraishi T, Watanabe M, Matsuura H, Kusano I, Yatani R, Stemmermann GN. The frequency of latent prostatic carcinoma in young males: The Japanese experience. In Vivo 1994 8 : 445 7.
12. Yatani R, Shiraishi T, Nakakuki K et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst 1965 80 : 683 7.
13. Watanabe M, Imai H, Kato H et al. Microsatellite instability in latent prostate cancers. Int J Cancer 1996 69 : 394 7.
14. Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 1992 69 : 2293 9.
15. Konishi N, Nakaoka S, Tsuzuki T et al. Progressive activity in latent prostate carcinoma defined by argyrophilic staining of the nucleolar organizer regions (AgNOR). Pathol Int 1994 44 : 297 302.
16. Luo J, Zha S, Gage WR et al. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 2002 62 : 2220 26.
17. Rubin MA, Zhou M, Dhanasekaran SM et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002 287 : 1662 70.
18. Jiang Z, Woda BA. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy. Adv Anat Pathol 2004 11 : 316 21.
19. Takahashi S, Suzuki S, Takahashi S, Inaguma S, Asamoto M, Shirai T. Differences between latent and clinical prostate carcinomas: Lower cell proliferation activity in latent cases. Prostate 2006 66 : 211 17.
20. Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003 44 : 650 55.
21. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 349 : 215 24.
22. Andriole G, Bostwick D, Civantos F et al. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: Current state of knowledge. J Urol 2005 174 : 2098 104.
23. Andriole G, Bostwick D, Brawley O et al. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004 172 : 1314 17.
24. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994 330 : 1029 35.
25. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999 8 : 893 9.
26. Klein EA, Thompson IM, Lippman SM et al. SELECT: The selenium and vitamin E cancer prevention trial. Urol Oncol 2003 21 : 59 65.
27. Lippman SM, Goodman PJ, Klein EA et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005 97 : 94 102.
28. Neill MG, Fleshner NE. An update on chemoprevention strategies in prostate cancer for 2006. Curr Opin Urol 2006 16 : 132 7.
29. Jain MG, Hislop GT, Howe GR, Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: Findings from case-control studies in Canada. Nutr Cancer 1999 34 : 173 84.
30. Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case-control study of diet and prostate cancer. Br J Cancer 1997 76 : 678 87.
31. Kristal AR, Cohen JH. Tomatoes, lycopene, and prostate cancer. How strong is the evidence? Am J Epidemiol 2000 151 : 124 7 discussion 28-30.
32. Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. food and drug administration's evidence-based review for qualified health claims: Tomatoes, lycopene, and cancer. J Natl Cancer Inst 2007 99 : 1074 85.
33. Jatoi A, Ellison N, Burch PA et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003 97 : 1442 6.
34. Adams KF, Chen C, Newton KM, Potter JD, Lampe JW. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2004 13 : 644 8.
35. Chen L, Stacewicz-Sapuntzakis M, Duncan C et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001 93 : 1872 9.
36. Clark LC, Combs GF Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996 276 : 1957 63.
37. Heinonen OP, Albanes D, Virtamo J et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998 90 : 440 46.
38. Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996 334 : 1145 9.
39. Hoenjet KM, Dagnelie PC, Delaere KP, Wijckmans NE, Zambon JV, Oosterhof GO. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: A randomised placebo-controlled study. Eur Urol 2005 47 : 433 9 discussion 39-40.
40. Kucuk O, Sarkar FH, Sakr W et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001 10 : 861 8.
41. Takimoto CH, Glover K, Huang X et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003 12 : 1213 21.
42. Lucia MS, Bostwick DG, Bosland M et al. Workgroup I. Rodent models of prostate cancer. Prostate 1998 36 : 49 55.
43. Pollard M. The Lobund-Wistar rat model of prostate cancer. J Cell Biochem Suppl 1992 16H : 84 8.
44. Bosland MC, Prinsen MK. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz (a) anthracene, and 3,2′-dimethyl-4-aminobiphenyl, after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res 1990 50 : 691 9.
45. Shirai T, Takahashi S, Cui L et al. Experimental prostate carcinogenesis: Rodent models. Mutat Res 2000 462 : 219 26.
46. Pour PM. Prostatic cancer induced in MRC rats by N-nitrosobis (2-oxopropyl) amine and N-nitrosobis (2-hydroxypropyl) amine. Carcinogenesis 1983 4 : 49 55.
47. Shirai T, Sano M, Tamano S et al. The prostate: A target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res 1997 57 : 195 8.
48. Shirai T, Fukushima S, Ikawa E, Tagawa Y, Ito N. Induction of prostate carcinoma in situ at high incidence in F344 rats by a combination of 3,2′-dimethyl-4-aminobiphenyl and ethinyl estradiol. Cancer Res 1986 46 : 6423 6.
49. Katayama S, Fiala E, Reddy BS et al. Prostate adenocarcinoma in rats: Induction by 3,2′-dimethyl-4-aminobiphenyl. J Natl Cancer Inst 1982 68 : 867 73.
50. Katayama S, Matsumoto K, Kitamura H. Prostate gland carcinogenesis in rats. II. Dose-response study of 3,2′-dimethyl-4-aminobiphenyl. Proc Jpn Cancer Assoc 1984 43 : 63.
51. Imaida K, Sano M, Tamano S et al. Organ dependent enhancement of rat 3,2′-dimethyl-4-aminobiphenyl (DMAB) carcinogenesis by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP): Positive effects on the intestine but not the prostate. Carcinogenesis 2001 22 : 1295 9.
52. Imaida K, Tamano S, Kato K et al. Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. Carcinogenesis 2001 22 : 467 72.
53. Kato K, Takahashi S, Cui L et al. Suppressive effects of dietary genistin and daidzin on rat prostate carcinogenesis. Jpn J Cancer Res 2000 91 : 786 91.
54. Mori T, Imaida K, Tamano S et al. Beef tallow, but not perilla or corn oil, promotion of rat prostate and intestinal carcinogenesis by 3,2′-dimethyl-4-aminobiphenyl. Jpn J Cancer Res 2001 92 : 1026 33.
55. Shirai T, Kato K, Futakuchi M et al. Organ differences in the enhancing potential of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine on carcinogenicity in the prostate, colon and pancreas. Mutat Res 2002 506-507 : 129 36.
56. Akaza H, Tsukamoto S, Morita T et al. Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2′-dimethyl-4- aminobiphenyl (DMAB). Prostate Cancer Prostatic Dis 2000 3 : 115 19.
57. Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama Y. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 1998 82 : 531 7.
58. Sugimura T, Wakabayashi K, Nakagama H, Nagao M. Heterocyclic amines. Mutagens/carcinogens produced during cooking of meat and fish. Cancer Sci 2004 95 : 290 99.
59. Ito N, Hasegawa R, Sano M et al. A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis 1991 12 : 1503 6.
60. Ghoshal A, Preisegger KH, Takayama S, Thorgeirsson SS, Snyderwine EG. Induction of mammary tumors in female Sprague-Dawley rats by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and effect of dietary fat. Carcinogenesis 1994 15 : 2429 33.
61. Hasegawa R, Sano M, Tamano S et al. Dose-dependence of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine (PhIP) carcinogenicity in rats. Carcinogenesis 1993 14 : 2553 7.
62. Shirai T, Cui L, Takahashi S et al. Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. Cancer Lett 1999 143 : 217 21.
63. Futakuchi M, Hirose M, Imaida K et al. Chemoprevention of 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine-induced colon carcinogenesis by 1-O-hexyl-2,3,5-trimethylhydroquinone after initiation with 1,2-dimethylhydrazine in F344 rats. Carcinogenesis 2002 23 : 283 7.
64. Pollard M, Luckert PH, Schmidt MA. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate 1982 3 : 563 8.
65. Bosland MC. Animal models for the study of prostate carcinogenesis. J Cell Biochem Suppl 1992 16H : 89 98.
66. Bosland MC, Prinsen MK, Rivenson A et al. Induction of proliferative lesions of ventral prostate, seminal vesicle, and other accessory sex glands in rats by N-methyl-N-nitrosourea: Effect of castration, pretreatment with cyproterone acetate and testosterone propionate and rat strain. Prostate 1992 20 : 339 53.
67. Shirai T, Tamano S, Kato T, Iwasaki S, Takahashi S, Ito N. Induction of invasive carcinomas in the accessory sex organs other than the ventral prostate of rats given 3,2′-dimethyl-4-aminobiphenyl and testosterone propionate. Cancer Res 1991 51 : 1264 9.
68. Shirai T, Imaida K, Iwasaki S, Mori T, Tada M, Ito N. Sequential observation of rat prostate lesion development induced by 3,2′-dimethyl-4- aminobiphenyl and testosterone. Jpn J Cancer Res 1993 84 : 20 25.
69. Shirai T, Sano M, Imaida K, Takahashi S, Mori T, Ito N. Duration dependent induction of invasive prostatic carcinomas with pharmacological dose of testosterone propionate in rats pretreated with 3,2′-dimethyl-4- aminobiphenyl and development of androgen-independent carcinomas after castration. Cancer Lett 1994 83 : 111 16.
70. Shirai T, Tamano S, Sano M et al. Site-specific effects of testosterone propionate on the prostate of rat pretreated with 3,2′-dimethyl-4- aminobiphenyl: Dose-dependent induction of invasive carcinomas. Jpn J Cancer Res 1995 86 : 645 8.
71. Nakanishi H, Takeuchi S, Kato K et al. Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2′-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats. Jpn J Cancer Res 1996 87 : 1218 26.
72. Kato K, Takahashi S, Mori T et al. Establishment of transplantable rat prostate carcinomas from primary lesions induced by 3,2′-dimethyl-4- aminobiphenyl and testosterone. J Toxicol Pathol 1998 11 : 27 32.
73. Asamoto M, Hokaiwado N, Cho YM et al. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 2001 61 : 4693 700.
74. Green JE, Greenberg NM, Ashendel CL et al. Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate 1998 36 : 59 63.
75. Takahashi S, Inaguma S, Sakakibara M et al. DNA methylation in the androgen receptor gene promoter region in rat prostate cancers. Prostate 2002 52 : 82 8.
76. Iwasaki S, Kato K, Mori T, Takahashi S, Futakuchi M, Shirai T. Development of androgen-independent carcinomas from androgen-dependent preneoplastic lesions in the male accessory sex organs of rats treated with 3,2′-dimethyl-4-aminobiphenyl and testosterone propionate. Jpn J Cancer Res 1999 90 : 23 30.
77. Malfatti MA, Dingley KH, Nowell-Kadlubar S et al. The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is predictive of colon DNA adducts after a low-dose exposure in humans. Cancer Res 2006 66 : 10541 7.
78. Tang D, Liu JJ, Rundle A et al. Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis. Cancer Epidemiol Biomarkers Prev 2007 16 : 803 8.
79. Zhu J, Chang P, Bondy ML et al. Detection of 2-amino-1-methyl-6- phenylimidazo[4,5-b]-pyridine-DNA adducts in normal breast tissues and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2003 12 : 830 37.
80. Nelson CP, Kidd LC, Sauvageot J et al. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res 2001 61 : 103 9.
81. Cross AJ, Peters U, Kirsh VA et al. A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res 2005 65 : 11 79 84.
82. El-Zein R, Etzel CJ, Lopez MS, Gu Y, Spitz MR, Strom SS. Human sensitivity to PhIP: A novel marker for prostate cancer risk. Mutat Res 2006 601 : 1 10.
83. Cui L, Takahashi S, Tada M et al. Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: Results with 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP) and 3,2′-dimethyl-4-aminobiphenyl (DMAB) and relation to cytochrome P450s and N-acetyltransferase activity. Jpn J Cancer Res 2000 91 : 52 8.
84. Takahashi S, Tamano S, Hirose M et al. Immunohistochemical demonstration of carcinogen-DNA adducts in tissues of rats given 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP): Detection in paraffin-embedded sections and tissue distribution. Cancer Res 1998 58 : 4307 13.
85. Said MM, Hokaiwado N, Tang M et al. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by leuprorelin, a luteinizing hormone-releasing hormone agonist. Cancer Sci 2006 97 : 459 67.
86. Cho YM, Takahashi S, Asamoto M, Suzuki S, Tang M, Shirai T. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate Cancer Prostatic Dis 2007 [Epub ahead of print].
87. Lin Y, Kokontis J, Tang F et al. Androgen and its receptor promote Bax-mediated apoptosis. Mol Cell Biol 2006 26 : 1908 16.
88. Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY, Liao S. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res 2006 66 : 6482 6.
89. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 2005 65 : 2082 4.
90. Berger R, Febbo PG, Majumder PK et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004 64 : 8867 75.
91. Tsukamoto S, Akaza H, Imada S et al. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. J Natl Cancer Inst 1995 87 : 842 3.
92. Toda T, Tamura J, Okuhira T. Isoflavone content in commercial soybean foods. FFI J Jpn 1997 172 : 83 9.
93. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993 342 : 1209 10.
94. Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 2007 16 : 538 45.
95. Hikosaka A, Asamoto M, Hokaiwado N et al. Inhibitory effects of soy isoflavones on rat prostate carcinogenesis induced by 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis 2004 25 : 381 7.
96. Onozawa M, Kawamori T, Baba M et al. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J Cancer Res 1999 90 : 393 8.
97. Pollard M, Wolter W, Sun L. Prevention of induced prostate-related cancer by soy protein isolate/isoflavone-supplemented diet in Lobund-Wistar rats. In Vivo 2000 14 : 389 92.
98. Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate 2000 45 : 101 5.
99. Suzuki S, Takahashi S, Takahashi S et al. Expression of prothymosin alpha is correlated with development and progression in human prostate cancers. Prostate 2006 66 : 463 9.
100. Weinstein SJ, Wright ME, Pietinen P et al. Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 2005 97 : 396 9.
101. Vraka PS, Drouza C, Rikkou MP, Odysseos AD, Keramidas AD. Synthesis and study of the cancer cell growth inhibitory properties of alpha-, gamma-tocopheryl and gamma-tocotrienyl 2-phenylselenyl succinates. Bioorg Med Chem 2006 14 : 2684 96.
102. Jiang Q, Wong J, Ames BN. Gamma-tocopherol induces apoptosis in androgen-responsive LNCaP prostate cancer cells via caspase-dependent and independent mechanisms. Ann N Y Acad Sci 2004 1031 : 399 400.
103. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anti Cancer Res 2004 24 : 2783 840.
104. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: In vitro and in vivo studies and the underlying mechanisms. Int J Oncol 2003 23 : 17 28.
105. Stewart JR, Artime MC, O'Brian CA. Resveratrol: A candidate nutritional substance for prostate cancer prevention. J Nutr 2003 133 : 2440S 43S.
106. Jang M, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 1999 25 : 65 77.
107. Takahashi S, Azman S, Takeshita K, Shirai T. Suppression effect of prostate carcinogenesis by resveratrol in transgenic rat for adenocarcinoma of prostate (TRAP) model. In : Innovations in Prostate Cancer Research. Philadelphia : American Association of Cancer Research, 2006 A6.
108. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995 87 : 1767 76.
109. Gann PH, Ma J, Giovannucci E et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: Results of a prospective analysis. Cancer Res 1999 59 : 1225 30.
110. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: Review of the epidemiologic literature. J Natl Cancer Inst 1999 91 : 317 31.
111. Yamagishi T, Uemura H, Nakaigawa N, Noguchi K, Kubota Y. Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer. J Urol 2005 173 : 441.
112. Uemura H, Hasumi H, Kawahara T et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 2005 10 : 405 10.
113. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007 67 : 924 32.
114. Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006 66 : 822 30.
115. Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol 1991 30 : 133 40.